Mon panier

uPAR

uPAR Informations sur la molécule

Nom anglaisUrokinase plasminogen activator surface receptorNombre de médicaments commercialisés0
Nombre de médicaments cliniques7Alias de la cibleMonocyte activation antigen Mo3,U-PAR,uPAR,CD87,Urokinase-Type Plasminogen Activator (UPA) Receptor,URKR,U-Plasminogen Activator Receptor Form 2,CD87 Antigen,Plasminogen Activator, Urokinase Receptor,MO3
Phase de R&D la plus avancéePhase 3 Clinical
Nom anglaisUrokinase plasminogen activator surface receptor
Alias de la cibleMonocyte activation antigen Mo3,U-PAR,uPAR,CD87,Urokinase-Type Plasminogen Activator (UPA) Receptor,URKR,U-Plasminogen Activator Receptor Form 2,CD87 Antigen,Plasminogen Activator, Urokinase Receptor,MO3
Nombre de médicaments commercialisés0
Nombre de médicaments cliniques7
Phase de R&D la plus avancéePhase 3 Clinical

uPAR Liste de produits

  • Attribut

    Protein (17)Cell (2)Beads (1)

  • Bibliothèque de produits

    En ligne (20)

  • Espèces

    Human (12)Mouse (5)Cynomolgus (1)Rat (2)

  • Étiquette

    His Tag (9)His Tag & Avi Tag (5)Fc Tag (3)- (3)

  • Marqueur

    Unconjugated (9)Biotin-labeled (5)FITC Labeled (1)PE Labeled (1)APC Labeled (1)- (3)

uPARContexte de la molécule

Urokinase plasminogen activator surface receptor (U-PAR) is also known as PLAUR, Monocyte activation antigen Mo3, CD antigen CD87. PLAUR contains three UPAR/Ly6 domains. U-PAR is expressed in neurons of the rolandic area of the brain (at protein level) and is also expressed in the brain. PLAUR / CD87 interacts with MRC2, SRPX2 and SORL1. PLAUR / UPAR acts as a receptor for urokinase plasminogen activator and plays a role in localizing and promoting plasmin formation. U-PAR mediates the proteolysis-independent signal transduction activation effects of U-PA.

uPARAlias de la molécule

uPAR,PLAUR,CD87,MO3

Informations sur les médicaments cliniques

Nom anglaisCode de recherchePhase de R&DEntrepriseIndicationEssai clinique
Gallium-68 NOTA AE105CS-001; 68Ga-NOTA-AE105Phase 3 ClinicalCurasight Aps, RigshospitaletBone metastases; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Genital Neoplasms, Female; Glioblastoma; Hair Diseases; Head and Neck Neoplasms; Mesothelioma; Mouth Neoplasms; Neoplasms; Neuroendocrine Tumors; Oropharyngeal Neoplasms; Prostatic Neoplasms; Urinary Bladder Neoplasms
Details
WAL0921WAL0921; WAL-0921; WAL 0921Phase 2 ClinicalWalden Biosciences IncDiabetic Nephropathies; Glomerulonephritis, IGA; Glomerulonephritis, Membranous; Glomerulosclerosis, Focal Segmental; Kidney Diseases; Nephrosis, Lipoid; Renal Insufficiency, Chronic
Details
64Cu-DOTA-AE10564Cu-DOTA-AE105Phase 2 ClinicalRigshospitaletBreast Neoplasms; Prostatic Neoplasms; Urinary Bladder Neoplasms
Details
FG-001FG001; FG-001Phase 2 ClinicalFluoGuide ASBrain Neoplasms; Glioma; Head and Neck Neoplasms; Low-grade Glioma; Lung Neoplasms; Meningioma
Details
MNPR-101-Lu177MNPR-101-PCTA-177Lu; MNPR-101-Lu177Phase 1 ClinicalMonopar Therapeutics IncCarcinoma, Transitional Cell; Colorectal Neoplasms; Lung Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms
Details
MNPR-101-ZrMNPR-101-Zr; MNPR-101-DFO*-89ZrPhase 1 ClinicalMonopar Therapeutics Inc, Northstar Medical Radioisotopes LlcCarcinoma, Transitional Cell; Colorectal Neoplasms; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms
Details
KMHH-03KMHH-03; KMHH03Phase 1 ClinicalBeijing Kangming Haihui Biological Technology Co LtdBreast Neoplasms
Details
  • Informations sur la molécule
  • Liste de produits
  • Informations sur les médicaments cliniques